GO:0005168 neurotrophin TRKA receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005168 (neurotrophin TRKA receptor binding) is a molecular function defined as binding to a neurotrophin TRKA receptor.
• The term captures ligand-receptor interactions that initiate TRKA (NTRK1) signaling, a key pathway in neuronal survival, differentiation, and pain sensing [1,2].
• High-affinity binding involves a twisted affair between TRKA and p75NTR, which modulates ligand specificity and signaling output.
• TRKA can bind heterologous ligands such as NT-3 at specific hot spots, expanding the repertoire of neurotrophin signaling.
• Dysregulation of TRKA binding is implicated in cancers, chronic pain, and neuropathies, making it a therapeutic target [2,5,8].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of TRKA binding interfaces and downstream effects [6,7].
Description
GO:0005168, neurotrophin TRKA receptor binding, is a molecular function that describes the physical interaction between a neurotrophin ligand and the TRKA receptor (encoded by NTRK1). This binding event is the first step in a signaling cascade that controls neuronal survival, differentiation, and synaptic plasticity [1,2]. The term is distinct from generic receptor binding because it specifies the TRKA receptor as the binding partner, reflecting the unique structural and functional features of this receptor-ligand pair. Researchers study this function to understand how neurotrophins like nerve growth factor (NGF) and neurotrophin-3 (NT-3) engage TRKA and how perturbations contribute to disease [2,4]. The interaction is not a simple lock-and-key; it involves conformational changes and co-receptor interactions that fine-tune signaling. For example, the p75 neurotrophin receptor can enhance TRKA signaling by binding to Shc and augmenting its phosphorylation. Moreover, TRKA immunoglobulin-like domains have been shown to inhibit spontaneous activation of the receptor, highlighting the importance of regulated binding. Understanding GO:0005168 is therefore central to neurobiology, oncology, and pain research, where TRKA signaling is a validated therapeutic axis [2,5,8].
neurotrophin TRKA receptor binding At A Glance
| GO ID | GO:0005168 |
|---|---|
| GO term | neurotrophin TRKA receptor binding |
| Ontology | molecular_function |
| Synonym | neurotrophin TRKA receptor ligand |
| Definition | Binding to a neurotrophin TRKA receptor. |
| Major function | Mediates ligand-receptor interactions that initiate TRKA signaling, influencing neuronal survival, differentiation, and pain perception [1,2]. |
| Related receptor | TRKA (NTRK1), a receptor tyrosine kinase. |
| Key ligands | NGF, NT-3, NT-4/5 [1,4]. |
| Co-receptor | p75NTR (NGFR) modulates binding affinity and signaling [1,3]. |
What Is GO:0005168?
In our own words, GO:0005168 (neurotrophin TRKA receptor binding) is the molecular function of selectively and non-covalently interacting with a neurotrophin TRKA receptor. This includes the binding of neurotrophin ligands such as NGF, NT-3, or NT-4/5 to the TRKA receptor tyrosine kinase, as well as the binding of accessory proteins or peptides that modulate this interaction. The term is defined by the Gene Ontology as 'Binding to a neurotrophin TRKA receptor' and is synonymous with 'neurotrophin TRKA receptor ligand'.
Why Is neurotrophin TRKA receptor binding Important in Cell Biology?
GO:0005168 is important because it defines the molecular trigger for TRKA signaling, a pathway that is essential for the development and maintenance of the nervous system and is frequently dysregulated in human diseases [1,2]. Alterations in this binding function can lead to cancer, chronic pain, and neurodegenerative conditions, making it a prime target for therapeutic intervention [2,5,8].
• TRKA binding by NGF is critical for nociceptor function and pain sensitization.
• Dysregulated TRKA signaling is implicated in breast cancer, where NGF from venom or endogenous sources binds TRKA to promote tumor growth.
• Mast cell activation by NGF via TRKA contributes to trauma-induced heterotopic ossification.
• NT-3 can act as a heterologous ligand for TRKA, expanding the signaling repertoire beyond NGF.
• The p75NTR co-receptor enhances TRKA signaling by binding to Shc and augmenting phosphorylation.
• TRKA immunoglobulin-like domains prevent spontaneous activation, ensuring ligand-dependent signaling.
• RanBPM interacts with TRKA, potentially regulating its trafficking and signaling.
• Neuropilin-1 inhibition suppresses NGF signaling and nociception, highlighting additional modulators.
• TRKA binding is a target for pain therapeutics and cancer diagnostics [2,8].
• Understanding this function aids in designing CRISPR models to study neurotrophin signaling in health and disease [6,7].
Molecular Mechanism of neurotrophin TRKA receptor binding
Ligand recognition and binding interface
In simple terms: The neurotrophin ligand docks onto specific regions of the TRKA receptor.
The binding of neurotrophins to TRKA involves specific structural determinants. The immunoglobulin-like domains of TRKA form the ligand-binding interface, and these domains also inhibit spontaneous activation of the receptor in the absence of ligand. NT-3 can bind TRKA as a heterologous ligand at distinct 'hot spots', demonstrating that multiple neurotrophins can engage TRKA with different affinities. This binding is the first step in receptor activation and is governed by the complementary surfaces of the ligand and receptor.
Conformational changes and receptor activation
In simple terms: Binding causes the receptor to change shape and become active.
Upon ligand binding, TRKA undergoes conformational changes that lead to receptor dimerization and autophosphorylation. The interaction with p75NTR can modulate this process; p75NTR binds to Shc and augments its phosphorylation, thereby enhancing TRKA signaling. The twisted affair between high-affinity TRKA and p75NTR complexes suggests a complex interplay that fine-tunes the activation threshold.
Co-receptor and modulator interactions
In simple terms: Other proteins can join in to adjust how strongly the signal is sent.
The p75 neurotrophin receptor (NGFR) is a key modulator of TRKA binding and signaling. It can form high-affinity complexes with TRKA, and its presence alters ligand specificity and downstream outcomes. Additionally, proteins such as RanBPM interact with TRKA, potentially affecting its localization or activity. Neuropilin-1 has also been implicated in NGF signaling, as its inhibition suppresses NGF-induced nociception.
Regulation by phosphorylation and trafficking
In simple terms: After binding, the receptor is chemically modified and moved inside the cell to control the signal.
Ligand binding triggers autophosphorylation of TRKA on specific tyrosine residues, creating docking sites for adaptor proteins like Shc. This phosphorylation is enhanced by p75NTR. The activated receptor is then internalized and trafficked to different cellular compartments, where it can initiate distinct signaling cascades. The immunoglobulin-like domains of TRKA help prevent spontaneous activation, ensuring that signaling is tightly coupled to ligand binding.
Key Genes Involved in GO:0005168 neurotrophin TRKA receptor binding
The following genes and proteins are central to neurotrophin TRKA receptor binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NTRK1 | Encodes TRKA receptor tyrosine kinase; binds neurotrophins | Mutations and fusions are oncogenic; target for pain and cancer therapy [1,2] |
| NGF | Primary ligand for TRKA; activates survival and pain pathways | Key mediator of nociception and neuropathic pain [2,5] |
| NGFR | Encodes p75NTR; modulates TRKA binding affinity and signaling | Co-receptor that enhances TRKA signaling via Shc [1,3] |
| NTF3 | Encodes NT-3; can bind TRKA as heterologous ligand | Expands TRKA signaling repertoire; involved in neuronal development |
| NTF4 | Encodes NT-4/5; binds TRKA | Regulates synaptic plasticity and survival |
| SHC1 | Adaptor protein; binds phosphorylated TRKA | Mediates downstream MAPK signaling; phosphorylation enhanced by p75NTR |
| RANBP9 | Encodes RanBPM; interacts with TRKA | May regulate TRKA trafficking and signaling |
| NRP1 | Encodes Neuropilin-1; modulates NGF signaling | Inhibition suppresses NGF signaling and nociception |
| NTRK2 | Encodes TRKB; related neurotrophin receptor | Comparison for specificity studies |
| NTRK3 | Encodes TRKC; related neurotrophin receptor | Comparison for specificity studies |
| SORT1 | Encodes sortilin; interacts with neurotrophins | Modulates neurotrophin sorting and signaling |
| PLCG1 | Phospholipase C gamma 1; downstream of TRKA | Mediates TRKA-induced calcium signaling |
| PIK3CA | PI3 kinase subunit; downstream of TRKA | Promotes survival signaling |
| MAPK1 | ERK2; downstream of TRKA | Regulates proliferation and differentiation |
| AKT1 | Downstream of TRKA | Promotes cell survival |
| FRS2 | Adaptor protein; binds TRKA | Links TRKA to MAPK and PI3K pathways |
| GRB2 | Adaptor protein; binds TRKA | Mediates Ras-MAPK activation |
How Is neurotrophin TRKA receptor binding Regulated?
The binding of neurotrophins to TRKA is regulated at multiple levels. Ligand availability is controlled by expression, secretion, and extracellular matrix interactions. Receptor levels and localization are modulated by transcription, trafficking, and degradation. Co-receptors such as p75NTR and Neuropilin-1 can enhance or inhibit binding and signaling [1,2,3]. Post-translational modifications of TRKA, including phosphorylation and ubiquitination, affect its activity and turnover. Additionally, proteins like RanBPM interact with TRKA and may influence its function. These regulatory mechanisms ensure that TRKA signaling is tightly controlled in space and time.
neurotrophin TRKA receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NTRK1 | Cancers (e.g., breast, lung), pain disorders | Knockout or point-mutation cell lines to study ligand binding and signaling [1,8] |
| NGF | Chronic pain, neuropathic pain | Overexpression or knockout in neuronal cell lines to assess nociception [2,5] |
| NGFR | Neurodegeneration, pain modulation | Knock-in of tagged p75NTR to study TRKA complex formation [1,3] |
| NTF3 | Neurodevelopmental disorders | Point mutations at TRKA hot spots to alter NT-3 binding |
| NRP1 | Pain, cancer | Knockout or knockdown to assess NGF signaling suppression |
TRKA binding in cancer
Dysregulated TRKA signaling is oncogenic in several cancers. NTRK1 fusions and mutations lead to constitutive kinase activity, driving tumor growth. In breast cancer, NGF from Russell's viper venom shows high-affinity binding to TRKA expressed on cancer cells, and fluorescence-labeled RVV-NGFa has been proposed for clinical diagnosis. Targeting TRKA binding or its downstream effectors is a therapeutic strategy in TRKA-addicted cancers.
TRKA binding in pain and nociception
NGF binding to TRKA on nociceptors is a key driver of pain sensitization. Inhibition of Neuropilin-1 suppresses NGF signaling and nociception in pain models, highlighting the importance of modulatory interactions. Mast cell activation by NGF via TRKA contributes to trauma-induced heterotopic ossification, a painful condition. Thus, blocking TRKA binding or its co-receptor interactions is a promising analgesic approach.
TRKA binding in neurodevelopment and neurodegeneration
TRKA binding by neurotrophins is essential for neuronal survival and differentiation. Disruption of this function can lead to neurodegenerative phenotypes. The p75NTR co-receptor enhances TRKA signaling, and its dysregulation may contribute to neuronal loss. Understanding the structural basis of TRKA binding, including the role of immunoglobulin-like domains, may inform strategies to promote neuronal survival.
From neurotrophin TRKA receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TRKA binding abolish NGF-induced survival? | NTRK1 knockout cell line (e.g., PC12 or primary neurons) |
| Which residues mediate high-affinity NT-3 binding? | Point mutations in TRKA immunoglobulin-like domains |
| How does p75NTR modulate TRKA signaling? | Knock-in of tagged NGFR or Shc mutants |
| Can overexpression of NGF drive nociception? | Overexpression of NGF in neuronal cell lines or animal models [2,5] |
| What is the effect of RanBPM on TRKA trafficking? | Knockout or overexpression of RANBP9 in cell lines |
| Can TRKA binding be targeted in cancer? | Patient-derived xenografts or cell lines with NTRK1 fusions [1,8] |
How to Study the neurotrophin TRKA receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding affinity and kinetics | Characterize TRKA-ligand interactions |
| Isothermal titration calorimetry (ITC) | Thermodynamics of binding | Validate high-affinity complexes |
| Western blot | Phosphorylation of TRKA and downstream targets | Assess activation after ligand binding |
| CRISPR knockout screen | Genes required for TRKA signaling | Identify modulators of NGF response |
| Proximity ligation assay (PLA) | In situ protein-protein interactions | Detect TRKA-p75NTR complexes |
| Fluorescence microscopy | Localization of TRKA and ligands | Track receptor internalization |
| ELISA | Quantitative binding | Measure ligand-receptor interaction in vitro |
| Co-immunoprecipitation | Protein complex formation | Confirm TRKA-Shc interaction |
Binding assays (SPR, ITC, ELISA)
Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) measure the affinity and kinetics of neurotrophin-TRKA interactions. ELISA-based assays can quantify binding in cell lysates or with purified proteins. These methods are used to characterize wild-type and mutant TRKA receptors [4,6].
Phosphorylation and signaling assays
Western blotting with phospho-specific antibodies detects TRKA autophosphorylation and downstream activation of Shc, MAPK, and AKT. These assays are essential to link binding events to functional outcomes [3,6].
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes that modulate TRKA binding and signaling. For example, knocking out candidate co-receptors like NGFR or NRP1 can reveal their contribution to NGF-induced phenotypes [2,3].
Imaging and proximity assays
Fluorescence microscopy and proximity ligation assays (PLA) visualize TRKA-ligand complexes and their subcellular localization. These techniques help confirm binding in situ and track receptor trafficking [1,7].
How CRISPR Can Be Used to Study GO:0005168 neurotrophin TRKA receptor binding
Knockout
CRISPR knockout of NTRK1 or its ligands (NGF, NTF3) abolishes neurotrophin TRKA receptor binding, providing a clean background to study downstream effects. For example, NTRK1 knockout cells fail to activate MAPK in response to NGF, confirming the specificity of the pathway. Knockout of NGFR can reveal its modulatory role in TRKA signaling.
Point Mutation
Point mutations in the TRKA ligand-binding domain (e.g., immunoglobulin-like domains) can disrupt specific interactions with neurotrophins. Such mutations help map the binding interface and identify residues critical for high-affinity binding, as demonstrated for NT-3 hot spots. Point mutations in Shc can also block p75NTR-enhanced phosphorylation.
Knock-in
Knock-in of tagged TRKA (e.g., HA or GFP) allows visualization and purification of the receptor for interaction studies. Knock-in of disease-associated mutations (e.g., NTRK1 fusions) can model oncogenic signaling. Tagged p75NTR knock-in enables tracking of co-receptor complexes.
Overexpression
Overexpression of NGF or TRKA can amplify binding and signaling, useful for studying gain-of-function phenotypes such as pain sensitization or tumor growth [2,5]. Overexpression of RanBPM can test its effect on TRKA trafficking. Overexpression systems are also used to produce recombinant proteins for structural studies.
How EDITGENE Supports neurotrophin TRKA receptor binding Research
Researchers studying neurotrophin TRKA receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand-receptor interactions, downstream signaling, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of genes implicated in GO:0005168.
Contact EDITGENE today to design your custom CRISPR model for neurotrophin TRKA receptor binding research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PIK3R1 Knockout HEK293T Cell Line | EDJ-KQ159 | Human | 5295 | Details Get a Quote |
| EFNA5 Knockout HEK293 Cell Line | EDJ-KQ164 | Human | 1946 | Details Get a Quote |
| PIK3R1 Knockout HEK293 Cell Line | EDJ-KQ520 | Human | 5295 | Details Get a Quote |
| PLCG1 Knockout HEK293 Cell Line | EDJ-KQ582 | Human | 5335 | Details Get a Quote |
| SHC1 Knockout HEK293 Cell Line | EDJ-KQ659 | Human | 6464 | Details Get a Quote |
| FRS2 Knockout HEK293 Cell Line | EDJ-KQ2171 | Human | 10818 | Details Get a Quote |
| PLCG1 Knockout HeLa Cell Line | EDJ-KQ18033 | Human | 5335 | Details Get a Quote |
| PLCG1 Knockout A-549 Cell Line | EDJ-KQ19000 | Human | 5335 | Details Get a Quote |
| PLCG1 Knockout HCT 116 Cell Line | EDJ-KQ19001 | Human | 5335 | Details Get a Quote |
| EFNA5 Knockout A-549 Cell Line | EDJ-KQ19147 | Human | 1946 | Details Get a Quote |
| EFNA5 Knockout HeLa Cell Line | EDJ-KQ19149 | Human | 1946 | Details Get a Quote |
| PIK3R1 Knockout A-549 Cell Line | EDJ-KQ18855 | Human | 5295 | Details Get a Quote |
| PIK3R1 Knockout HCT 116 Cell Line | EDJ-KQ18856 | Human | 5295 | Details Get a Quote |
| PIK3R1 Knockout HeLa Cell Line | EDJ-KQ18857 | Human | 5295 | Details Get a Quote |
| SHC1 Knockout A-549 Cell Line | EDJ-KQ20524 | Human | 6464 | Details Get a Quote |
Frequently Asked Questions About neurotrophin TRKA receptor binding
What is GO:0005168?
GO:0005168 is the Gene Ontology molecular function term for neurotrophin TRKA receptor binding, defined as binding to a neurotrophin TRKA receptor.
What genes are involved in neurotrophin TRKA receptor binding?
Key genes include NTRK1 (TRKA), NGF, NGFR (p75NTR), NTF3, NTF4, SHC1, and modulators like NRP1 and RANBP9 [1,2,3,4,7].
What is the function of TRKA receptor binding?
It initiates signaling cascades that control neuronal survival, differentiation, and pain perception [1,2].
How does p75NTR affect TRKA binding?
p75NTR forms high-affinity complexes with TRKA and enhances signaling by binding to Shc and augmenting its phosphorylation [1,3].
Can NT-3 bind to TRKA?
Yes, NT-3 can act as a heterologous ligand for TRKA, binding at specific hot spots.
What diseases are associated with TRKA binding?
Cancers (e.g., breast cancer), chronic pain, and neurodegenerative conditions [1,2,5,8].
How can I study neurotrophin TRKA receptor binding?
Use binding assays (SPR, ITC), phosphorylation assays, CRISPR screens, and imaging techniques [3,4,6].
What CRISPR models are available for TRKA research?
Knockout, point mutation, knock-in, and overexpression models can be generated for NTRK1 and related genes [6,7].
Is TRKA a therapeutic target?
Yes, TRKA and its binding partners are targets for pain relief and cancer therapy [2,8].
What is the role of RanBPM in TRKA signaling?
RanBPM interacts with TRKA and may regulate its trafficking and signaling.
Conclusion
GO:0005168 (neurotrophin TRKA receptor binding) is a fundamental molecular function that governs neurotrophin signaling in health and disease. Its precise definition and the availability of CRISPR tools enable researchers to dissect the binding interfaces, co-receptor interactions, and downstream pathways with unprecedented resolution. Understanding this function opens avenues for therapeutic intervention in cancer, pain, and neurodegeneration.
References
- 1. Conroy JN et al.. 2022. High-affinity TrkA and p75 neurotrophin receptor complexes: A twisted affair.. J Biol Chem 298(3):101568 PMID: 35051416
- 2. Peach CJ et al.. 2024. Neuropilin-1 inhibition suppresses nerve growth factor signaling and nociception in pain models.. J Clin Invest 135(4) PMID: 39589827
- 3. Epa WR et al.. 2004. The p75 neurotrophin receptor enhances TrkA signalling by binding to Shc and augmenting its phosphorylation.. J Neurochem 89(2):344-53 PMID: 15056278
- 4. Ivanisevic L et al.. 2007. TrkA receptor "hot spots" for binding of NT-3 as a heterologous ligand.. J Biol Chem 282(23):16754-63 PMID: 17439940
- 5. Jiang T et al.. 2024. Mast cell activation by NGF drives the formation of trauma-induced heterotopic ossification.. JCI Insight 10(1) PMID: 39589893
- 6. Arevalo JC et al.. 2000. TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor.. Mol Cell Biol 20(16):5908-16 PMID: 10913174
- 7. Yuan Y et al.. 2006. The Ran binding protein RanBPM interacts with TrkA receptor.. Neurosci Lett 407(1):26-31 PMID: 16959415
- 8. Islam T et al.. 2020. Nerve growth factor from Indian Russell's viper venom (RVV-NGFa) shows high affinity binding to TrkA receptor expressed in breast cancer cells: Application of fluorescence labeled RVV-NGFa in the clinical diagnosis of breast cancer.. Biochimie 176:31-44 PMID: 32585227
